-
Product Insights
Cutaneous Squamous Cell Carcinoma (cSCC) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Cutaneous Squamous Cell Carcinoma (cSCC) Clinical Trial Report Overview A total of 161 cSCC clinical trials were conducted as of February 2024. The following are some of the key highlights of the Cutaneous Squamous Cell Carcinoma (cSCC) clinical trial report : As of February 2024, North America led the cSCC clinical trials landscape with more than 45% of the clinical trials conducted there. In 2024, Merck conducted the highest number of cSCC clinical trials. The cSCC clinical trial report provides...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6341 in Chronic Cough
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6341 in Chronic Cough report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6341 in Chronic Cough Drug Details: RG-6341 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tazemetostat Hydrobromide in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tazemetostat Hydrobromide in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tazemetostat Hydrobromide in Marginal Zone B-cell Lymphoma Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tuspetinib in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tuspetinib in Refractory Acute Myeloid Leukemia Drug Details: Tuspetinib (HM-43239) is under development for the...
-
Product Insights
NewKeloids – Drugs In Development, 2024
Empower your strategies with our Keloids – Drugs In Development, 2024 report and make more profitable business decisions. Keloids are a growth of extra scar tissue where the skin has healed after an injury. Symptoms include flesh-colored, red, or pink, lumpy (nodular) or ridged scars, which can become irritated from friction against clothing and tender and itchy. Risk factors include age and family history. Treatment includes corticosteroids, radiation, surgical removal, and silicone gel or patches. The Keloids drugs in development market...
-
Product Insights
NewHemochromatosis – Drugs In Development, 2024
Empower your strategies with our Hemochromatosis – Drugs In Development, 2024 report and make more profitable business decisions. Hemochromatosis is an iron disorder in which the body simply retains too much iron. Symptoms include joint pain, abdominal pain, fatigue, weakness, diabetes, liver failure, and heart failure. Risk factors include family history, alcoholism, taking dietary supplements with iron or vitamin C, and history of diabetes, heart disease, or liver disease. The Hemochromatosis drugs in development market research report provide comprehensive information on...
-
Product Insights
NewHypertrophic Scars – Drugs In Development, 2024
Empower your strategies with our Hypertrophic Scars – Drugs In Development, 2024 report and make more profitable business decisions. A hypertrophic scar is a cutaneous condition characterized by deposits of excessive amounts of collagen which gives rise to a raised scar. It occurs when the body overproduces collagen, which causes the scar to be raised above the surrounding skin. Hypertrophic scars take the form of a red raised lump on the skin for lighter pigmented skin and the form of dark...
-
Product Insights
NewPrimary Sclerosing Cholangitis – Drugs In Development, 2024
Empower your strategies with our Primary Sclerosing Cholangitis – Drugs In Development, 2024 report and make more profitable business decisions. Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness, and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs. The Primary Sclerosing Cholangitis drugs in development...